Press Releases - Oxford Biomedica

Oxford BioMedica plc (“Oxford BioMedica” or “the Group”) (LSE: OXB), a leading gene and cell therapy group, is pleased to announce that Dr. Lorenzo Tallarigo will be appointed as Non-Executive Chairman of the Group on 1 February 2016.

From 2008 to 2014 Dr.Tallarigo was a member of the Board, and Chairman from 2011, of Intercept Pharmaceuticals (Nasdaq:ICPT). Intercept Pharmaceuticals is a biopharmaceutical company focused on the development and…

Business Update

Oxford, UK – 4 November 2015: Oxford BioMedica plc (“Oxford BioMedica” or “the Group”) (LSE: OXB), a leading gene and cell therapy group, is pleased to announce the following business…

GSK Exercises Option on Oxford BioMedica’s LentiVector® Technology Patents

Oxford, UK – 28 October 2015: Oxford BioMedica plc (“Oxford BioMedica” or “the Group”) (LSE: OXB), a leading gene and cell therapy group, announces that GlaxoSmithKline PLC (GSK) has exercised an…

INTERIM RESULTS FOR THE SIX MONTHS ENDED 30 JUNE 2015

Oxford, UK – 27 August 2015: Oxford BioMedica plc (LSE: OXB), (“OXB” or “the Group”) a leading gene and cell therapy group, today announces interim results for the six months…

Oxford BioMedica: Notice of Interim Results Results date: 27 August 2015

Oxford, UK – 6 August 2015: Oxford BioMedica plc (LSE: OXB), (“OXB” or “the Group”) a leading gene and cell therapy group, will be announcing its interim results for the…

Oxford BioMedica to present at JMP Securities Life Sciences Conference 2015 in New York and to attend ROTH Healthcare Day in London

Oxford, UK – 23 June 2015: Oxford BioMedica plc (“Oxford BioMedica” or “the Group”) (LSE: OXB), a leading gene and cell therapy group, announces that Chief Executive Officer John Dawson will…

Oxford BioMedica to Present at Jefferies 2015 Global Healthcare Conference, New York

Oxford, UK – 29 May 2015: Oxford BioMedica plc (LSE: OXB) (“the Group”), a leading gene and cell therapy group, today announces that John Dawson, Chief Executive Officer of Oxford BioMedica,…

Oxford BioMedica Appoints Daniel Soland as Non-Executive Director to the Board

London, UK – 7 May 2015: Oxford BioMedica plc (“Oxford BioMedica” or “the Group”) (LSE:OXB), a leading gene and cell therapy group, today announces the appointment of Daniel Soland as a…

Oxford BioMedica Interim Management Statement

London, UK – 7 May 2015: Oxford BioMedica plc (“Oxford BioMedica” or “the Group” or “OXB”) (LSE:OXB), a leading gene and cell therapy Group, today publishes its interim management statement for…

Oxford BioMedica’s Phase I study results with RetinoStat® were selected as a “Hot Topic” at the Association for Research in Vision and Ophthalmology conference in US

Oxford, UK – 5 May 2015: Oxford BioMedica plc (LSE: OXB), (“the Company”) the leading gene and cell therapy based biopharmaceutical company, today announces that results from the 21 patients in…

Oxford BioMedica announces that a summary of the 12 month and three year follow up data from the Phase I/II study with ProSavin® was presented at the AANS conference in the US

Oxford, UK – 5 May 2015: Oxford BioMedica plc (LSE: OXB) (“the Group”), a leading gene and cell therapy group, today announces that Professor Stéphane Palfi MD, PhD has presented…

Oxford BioMedica secures $50 million loan facility with Oberland Capital to support the Group’s growth ambitions

Oxford, UK – 1 May 2015: Oxford BioMedica plc (LSE: OXB), (“Oxford BioMedica” or the “Group”) a leading gene and cell therapy Group, today announces that it has secured a $50…